What is Rasio?
Rasio Therapeutics, Inc. operates at the intersection of advanced computational science and medicinal chemistry. By leveraging cutting-edge computer-aided drug design technology, the company addresses complex biological targets that have historically remained inaccessible to traditional pharmaceutical approaches. Through a strategic partnership with SilcsBio, a recognized leader in computational drug discovery, Rasio is systematically building a pipeline of small-molecule therapeutics. The firm is currently prioritizing oncology, targeting areas of significant unmet medical need where precision and molecular efficacy are paramount to improving patient outcomes.
How much funding has Rasio raised?
Rasio has raised a total of $1.5M across 1 funding round:
Unspecified
$1.5M
Unspecified (2021): $1.5M with participation from Bluedot Bio
Key Investors in Rasio
Bluedot Bio
A venture capital firm specializing in early-stage biotech and life sciences, focusing on companies that utilize computational platforms to solve complex medical challenges.
What's next for Rasio?
With this major enterprise-level funding, Rasio is poised to transition from its initial development phase into a more robust operational scale. The capital will likely be deployed to expand its internal research capabilities, refine its computational modeling algorithms, and advance its lead oncology candidates through preclinical validation. As the company continues to leverage its technological edge, the focus will shift toward establishing proof-of-concept for its novel disease targets, potentially setting the stage for future clinical trials and strategic pharmaceutical collaborations. The firm remains a key entity to watch within the biotech sector as it seeks to translate digital molecular insights into tangible clinical breakthroughs.
See full Rasio company page
